Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Dose Escalation, Controlled, Randomized Study to Evaluate Safety, Early Bactericidal Activity (EBA) and Pharmacokinetics of TBA-7371 in Adult Patients With Rifampicin-sensitive Pulmonary Tuberculosis

NCT04176250 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.

NCT NCT04176250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04176250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Dose Escalation, Controlled, Randomized Study to Evaluate Safety, Early Bactericidal Activity (EBA) and Pharmacokinetics of TBA-7371 in Adult Patients With Rifampicin-sensitive Pulmonary Tuberculosis
Lead sponsor
Gates Medical Research Institute
Phase
Phase 2
Overall status
Completed
Start date
January 16, 2020
Completion date
October 5, 2022
Enrollment
93 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis